Format

Send to

Choose Destination
Orv Hetil. 2012 Apr 1;153(13):499-504. doi: 10.1556/OH.2012.29308.

[The potential use of cannabidiol in the therapy of metabolic syndrome].

[Article in Hungarian]

Author information

1
Semmelweis Egyetem, Gyógyszerésztudományi Kar Farmakognóziai Intézet Budapest Üllői út 26. 1085. woww1165@gmail.com

Abstract

Cannabidiol, a cannabinoid and serotonin receptor antagonist, may alleviate hyperphagia without the side effects of rimonabant (for example depression and reduced insulin sensitivity). Similar to the peroxisome proliferator-activated receptor-gamma agonists, it may also help the differentation of adipocytes. Cannabidiol has an immunomodulating effect, as well, that helps lessen the progression of atherosclerosis induced by high glucose level. It may also be effective in fighting ischaemic diseases, the most harmful complications of metabolic syndrome. However, it can only be administered as an adjuvant therapy because of its low binding potency, and its inhibiting effect of cytochrome P450 enzymes should also be considered. Nevertheless, it may be beneficially used in adjuvant therapy because of its few side effects.

PMID:
22430005
DOI:
10.1556/OH.2012.29308
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center